GLP1R and Werner syndrome: Several classes of drugs have been reported for the treatment of WS, including dantrolene sodium (Nguyen et al., 2020), 4-phenylbutyric acid (4-PBA) and tauroursodeoxycholic acid (TUDCA) (Kitamura et al., 2022), glucagon-like peptide (GLP)-1 receptor agonists (Sedman et al., 2016; Kondo et al., 2018), and valproic acid (Kakiuchi et al., 2009).